RE: RNS28 Sep 2020 08:05
Outlook
· Pipeline health continuing through H2 2020 with 14 non-contracted tender opportunities worth a total potential contract value of €66 million, with a forecast of 13 new commercial offers and seven exclusivity contracts in H2 2020.
· Of over 40 opportunities and projects in our pipeline at end of H1 2020, more than half are expected to receive development capital from EQTEC as well as our partners. The acceleration is expected to drive us to closing deals more rapidly and deepening our partnerships.
· We will continue building and deepening partnerships in Europe, the USA and Asia toward increased support from EPC and development partners who can drive projects that deploy EQTEC technology in those markets.
· In parallel, we will continue to focus further on technology innovation and roadmap development toward maintaining our pre-eminence in advanced gasification, further developing it for a wider variety of applications for now and for the future.
· In H2 2020, we face some slowdown in closing deals as banks and government institutions grapple with the impacts of Covid-19 and we anticipate delays with financial close for some projects. We do not anticipate any contract cancellations or long-term postponements and expect to recover pace in 2021.
· As our sales and deal closing expertise scales, we will look to invest in the further development of our partnerships and disciplines with execution and project delivery. We expect to invest further in operational leadership and capabilities to ensure our technology is deployed to ensure the best value for our shareholders and wider stakeholders.
Sign In
Follow the stocks
